Abstract | OBJECTIVE: METHODS:
Peptides were synthesized according to the sequences of known natural ligands of HLA-B27 or B39 and were tested for their binding to HLA-B*3901 and B*2705 by quantitative peptide binding assay, using a TAP-deficient RMA-S cell line transfected with human beta2-microglobulin and HLA class I heavy chain genes. RESULTS: Four of the 10 HLA-B27 binding peptides significantly bound to HLA-B*3901. All 4 peptides had hydrophobic/ aromatic amino acids (Leu or Phe) at the C-terminus. In contrast, peptides with basic residues (Lys, Arg) or Tyr at the C-terminus did not bind to B*3901. In parallel experiments, 1 of the 2 natural ligands of HLA-B*3901 was found to bind to B*2705. CONCLUSION: A subset of natural HLA-B27 ligands was capable of binding to B*3901. In addition to Arg at position 2 (Arg2), hydrophobic/aromatic C-terminal residues, such as Leu or Phe, seemed to be crucial for the cross-specificity. These results suggested that HLA-B27 and B39 recognize overlapping peptide repertoires, supporting the hypothesis that the peptides presented by both of these class I antigens play a role in the pathogenesis of SpA.
|
Authors | Y Sobao, N Tsuchiya, M Takiguchi, K Tokunaga |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 42
Issue 1
Pg. 175-81
(Jan 1999)
ISSN: 0004-3591 [Print] United States |
PMID | 9920028
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- HLA-B Antigens
- HLA-B27 Antigen
- HLA-B39 Antigen
- Peptides
|
Topics |
- Amino Acid Sequence
- Antibody Specificity
- Binding Sites, Antibody
- Cross Reactions
- Genes, Overlapping
- HLA-B Antigens
(immunology)
- HLA-B27 Antigen
(immunology)
- HLA-B39 Antigen
- Humans
- Joint Diseases
(etiology)
- Peptides
(genetics, immunology, metabolism)
- Protein Binding
(genetics)
- Spinal Diseases
(etiology)
- Transfection
|